

Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study.

JOURNAL OF HEADACHE AND PAIN

Giorgio Sandrini; Armando Perrotta*; Cristina Tassorelli; Paola Torelli; Filippo Brighina; Grazia Sances; Giuseppe Nappi

*Corresponding author

Armando Perrotta, MD, PhD

Headache Science Center, IRCCS “C. Mondino Institute of Neurology” Foundation

Via Mondino 2, 27100 Pavia, Italy

Tel.: +39 0382 380435 Fax: +39 0382 380448 E-mail: armando.perrotta@mondino.it

Online Resource 2

Figure 1,2,3

Mean change (\pm SE) from baseline in headache pain intensity (Fig.1) and in disability measures Migraine Disability Assessment Scale (MIDAS) (Fig. 2) and Headache Impact Test (HIT)-6 (Fig. 3) at both 4 and 12 week after BoNTA or placebo in MOH patients with pericranial muscle tenderness.

Figure 1




Figure 2




Figure 3

